about
Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse modelBiological markers of amyloid beta-related mechanisms in Alzheimer's diseaseModeling an anti-amyloid combination therapy for Alzheimer's disease.Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptorsBeneficial catalytic immunity to abeta peptide.Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody librariesIn silico design of BACE1 inhibitor for Alzheimer's disease by traditional Chinese medicine.Clinical applications of a peptide-based vaccine for glioblastoma.Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.Update on the pharmacological treatment of Alzheimer's diseaseWhy pleiotropic interventions are needed for Alzheimer's disease.Amyloid-beta immunotherapy for Alzheimer's diseaseA retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Anti-amyloid-β-mediated positron emission tomography imaging in Alzheimer's disease mouse brainsNovel immunological approaches for the treatment of Alzheimer's disease.Immunomodulation for prion and prion-related diseases.Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimagingCurrent and future treatments for Alzheimer's diseaseIncreased accumulation of intraneuronal amyloid beta in HIV-infected patients.Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathologyA dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD miceLong-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's diseaseFor debate: substituting placebo controls in long-term Alzheimer's prevention trials.Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.Drosophila models of proteinopathies: the little fly that could.Could immunomodulation be used to prevent prion diseases?Treatment of Alzheimer's Disease with Repetitive Transcranial Magnetic Stimulation Combined with Cognitive Training: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study.Active immunotherapy for Alzheimer's disease.Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literatureα-Synuclein oligomers and clinical implications for Parkinson disease.The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments.Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesisEarly intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease.Calcium dyshomeostasis and neurotoxicity of Alzheimer's beta-amyloid protein.Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease.Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy
P2860
Q24608911-A03484F7-DBD0-4E5D-ACFA-DBD348DDAE1FQ24622136-26481004-89CF-499B-B32E-F89DDD6BD48CQ30482113-906FA5C1-E690-4586-A4E3-6A5C7D4A3086Q30497637-4C37045D-ED07-4D8B-BAFE-50E3284E0663Q33549900-2C9EAFDE-9DD4-4F8C-878E-6B6913662323Q33572338-C5470370-BAEC-45FE-8A7A-BDDB601A992FQ33666808-199849F6-A649-4EF8-9E75-388EAD66EC99Q33668575-B3079022-8AFA-4314-84E3-655C800D83BBQ33742312-57895DB4-ED56-40D2-BE9E-BEB3860DD501Q33836947-41E41A23-C33A-497E-9A61-208548943210Q33876128-5ED95BA7-6FE4-447A-A41C-1362A4E55B8AQ33954737-22962220-E4BA-42C6-A0B4-EE1034F187D8Q34518856-B0618C04-A8B1-46CE-88C6-00089CE160E7Q34532633-362ADCAA-6E4E-4EBD-BCA0-0867C156F9A9Q34562675-CCD7E099-02BB-4251-89D2-0F68E7D175C6Q34565644-90E0FE3A-CD8C-4D0C-B93D-98FAB403C9C5Q34611770-A04CA57A-1B72-409C-A4E5-E1E98AD46CCCQ34646921-4BCF748D-90EC-4904-9BD0-B1D279CAF712Q34661343-3A18AB40-5190-4EF6-B133-4C2B81120ECCQ34943311-6FA98A2C-E1A7-4123-866E-DF77C47FF5E8Q35040016-4EB428D0-E197-486A-A9D8-66458A8A9033Q35300928-7ED05EA3-31E6-4237-A426-A145CACC4275Q35540628-6C210E28-EF65-48E9-8773-4E5899791EDFQ35579221-A67B2641-E4FC-4627-877D-D96667597CEDQ35695716-15CEC326-A229-4A89-8640-ED623B49E17BQ35791494-2E4B42CE-8426-4DD4-90CE-0AB1BF2E67E1Q35875915-CACFD91C-20F8-45E5-AC2D-F865152E9CBFQ36460646-03D8CEE3-5135-4A7B-85FF-3E4D4FFE6581Q36575898-6A1CE2E6-D80E-4296-B9E1-4B2068375683Q36575903-66D9BD4B-F29E-4A65-893A-24CC22BE3A59Q36718306-B3D3F579-6577-4178-A5EB-7C6CF9095036Q37334202-4B421CFF-2457-4758-9DF0-B86BC702D4F0Q37336139-C681FA07-6402-4A74-AFA2-A5FFA1976392Q37364350-16D65AF2-D272-445B-93BB-EC0619D25EB7Q37464182-3A9670B1-1CFA-4B77-B2E7-F8E5F7F8CF67Q37588183-1CD7A75F-DAB6-4E5D-A009-0DE6C82EC167Q37623855-BAEBC55C-C123-47FC-A87B-6F231E5CC882Q37655247-D12BCBDF-2F07-4B7B-8092-92E25F092A4CQ37681432-5E9428BE-2BA3-4D96-980C-D98B8A7615C3Q37685285-8B8FF702-16C0-4F7A-B834-0C56317A36CA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Amyloid-beta immunisation for Alzheimer's disease
@en
Amyloid-beta immunisation for Alzheimer's disease.
@nl
type
label
Amyloid-beta immunisation for Alzheimer's disease
@en
Amyloid-beta immunisation for Alzheimer's disease.
@nl
prefLabel
Amyloid-beta immunisation for Alzheimer's disease
@en
Amyloid-beta immunisation for Alzheimer's disease.
@nl
P2860
P1433
P1476
Amyloid-beta immunisation for Alzheimer's disease
@en
P2093
Uwe Konietzko
P2860
P304
P356
10.1016/S1474-4422(08)70170-4
P577
2008-07-28T00:00:00Z